Low prothrombin time (prolonged Quick time) without known anticoagulant treatment
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Low prothrombin time found without known anticoagulant treatment
Laboratory tests (citrate tube)
- State on the prescription: “low PT off anticoagulant, to be investigated” (the laboratory scientist may then measure fibrinogen and factors on their own initiative) and any current treatment, in particular direct oral anticoagulant or antibiotic.
- PT and aPTT (repeat)
- Fibrinogen
- Factors II, V, VII and X (if PT remains low)
- ASTif needednon-French guidelineProlonged prothrombin time is frequent in cirrhosis [1]; liver function tests clarify the context. Authors’ opinion: no recommendation found on the work-up of an isolated low PT.
- ALTif needednon-French guidelineProlonged prothrombin time is frequent in cirrhosis [1]; liver function tests clarify the context. Authors’ opinion: no recommendation found on the work-up of an isolated low PT.
- Bilirubinif needednon-French guidelineProlonged prothrombin time is frequent in cirrhosis [1]; liver function tests clarify the context. Authors’ opinion: no recommendation found on the work-up of an isolated low PT.
- Serum albuminif needednon-French guidelineProlonged prothrombin time is frequent in cirrhosis [1]; liver function tests clarify the context. Authors’ opinion: no recommendation found on the work-up of an isolated low PT.
- FBC with platelets (if aPTT is also prolonged, or in case of bruising or bleeding)if needednon-French guidelinePT and aPTT both prolonged, bruising or bleeding: the American Family Physician review (2008) then raises disseminated intravascular coagulation, and the German recommendation (DGHO, 2025) places the full blood count in the baseline work-up of a bleeding tendency [2,3]. No French recommendation on this point.
Also consider
- aPTT also prolonged? If the aPTT is also prolonged, see the page “Isolated prolonged aPTT”.
Do not order
- INR to express a prothrombin time outside vitamin K antagonist treatment: the INR is calibrated and validated only for vitamin K antagonists [5].
Known cirrhosis: low prothrombin time before an invasive procedure
- No additional tests as a matter of course to “correct” the PT: discuss with the operator or the hepatologist.
Sources (17)
- Roberts LN, Lisman T, Stanworth S, Hernandez-Gea V, Magnusson M, Tripodi A, Thachil J. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20(1):39-47.
- Ballas M, Kraut EH. Bleeding and Bruising: A Diagnostic Work-up. Am Fam Physician. 2008;77(8):1117-1124.
- Gebhart J, Casini A, Knöfler R, Streif W, Zieger B, Trautmann-Grill K, Alesci RS, Kirschner M. Abklärung einer Blutungsneigung. Onkopedia, recommandation de la DGHO (société allemande d'hématologie et d'oncologie, avec les sociétés autrichienne et suisse), état août 2025.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0126 (temps de Quick hors AVK), 0127 (INR), 0174, 1014, 1015, 1016, 1017 et 1032 (fibrinogène et facteurs).
- Agence européenne des médicaments. Xarelto (rivaroxaban) : résumé des caractéristiques du produit (information produit EPAR), rubrique 5.1, consulté le 11 octobre 2026.
- Agence européenne des médicaments. Eliquis (apixaban) : résumé des caractéristiques du produit (information produit EPAR), rubriques 4.4 et 5.1, consulté le 11 octobre 2026.
- Matthaiou AM, Tomos I, Chaniotaki S, Liakopoulos D, Sakellaropoulou K, Koukidou S, et al. Association of Broad-Spectrum Antibiotic Therapy and Vitamin E Supplementation with Vitamin K Deficiency-Induced Coagulopathy: A Case Report and Narrative Review of the Literature. J Pers Med. 2023;13(9):1349.
- Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243-52.
- Hughes PR, Lewis MN, Adams SS. Bleeding and Bruising: Primary Care Evaluation. Am Fam Physician. 2024;110(5):504-514.
- Studt JD, Meyer O, Müller J, Parmentier S, Quehenberger P, Sachs U, Sucker C. Diagnostik von Gerinnungsstörungen, Normwerte. Onkopedia, recommandation de la DGHO (société allemande d'hématologie et d'oncologie, avec les sociétés autrichienne et suisse), état septembre 2026.
- O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y ; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology. 2021;161(5):1615-1627.
- National Institute for Health and Care Excellence (NICE). Blood transfusion. Guideline NG24, novembre 2015, mise à jour 26 février 2026. Recommandations 1.9.2 et 1.9.3 (plasma frais congelé).
- Base de données publique des médicaments. COUMADINE 2 mg, résumé des caractéristiques du produit, extrait de la base publique (CIS 64631925).
- Agence européenne des médicaments. Xarelto (rivaroxaban) : résumé des caractéristiques du produit (information produit EPAR), rubrique 5.1.
- Agence européenne des médicaments. Eliquis (apixaban) : résumé des caractéristiques du produit (information produit EPAR), rubrique 5.1.
- Agence européenne des médicaments. Pradaxa (dabigatran étexilate) : résumé des caractéristiques du produit (information produit EPAR), rubrique 4.4.
- Matthaiou AM, et al. Association of Broad-Spectrum Antibiotic Therapy and Vitamin E Supplementation with Vitamin K Deficiency-Induced Coagulopathy: A Case Report and Narrative Review. J Pers Med. 2023;13(9):1349.